Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanfanercept (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms VELOS-2
  • Sponsors HanAll Biopharma

    • Most Recent Events

    • 15 Nov 2022 According to a HanAll Biopharma media release, results from the study have been presented at the World Cornea Congress VIII.
    • 29 Jul 2021 Status changed from recruiting to completed, according to a HanAll Biopharma media release.
    • 28 Jan 2020 According to a HanAll Biopharma media release, the final results of this phase III study will be presented at upcoming international ophthalmologic meetings after completion of biomarker and sub-group analyses.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top